NILOTINIB
| Brand name | CAVHANZA |
|---|---|
| Active ingredient | NILOTINIB |
| Strength | 60MG |
| Dosage form | TABLET, ORALLY DISINTEGRATING |
| Route | ORAL |
| Modality | Small molecule |
| FDA approval | May 2026 |
| Marketing status | RX |
| Patent | Expires | Type |
|---|---|---|
| 11559485 | April 2041 | product |
| 12016861 | January 2041 | use U-4555 |
| 11389450 | January 2041 | use U-4557 |
| 12029740 | January 2041 | product |
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.